Nymox Pharmaceutical Corp
NYMX
NYMX was delisted on the 6th of July, 2023.
29 hedge funds and large institutions have $1.99M invested in Nymox Pharmaceutical Corp in 2016 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 5 increasing their positions, 5 reducing their positions, and 6 closing their positions.
0% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 5
0.04% less ownership
Funds ownership: 1.51% → 1.47% (-0.04%)
3% less funds holding
Funds holding: 30 → 29 (-1)
17% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 6
20% less capital invested
Capital invested by funds: $2.48M → $1.99M (-$496K)
62% less call options, than puts
Call options by funds: $593K | Put options by funds: $1.54M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Marshall Wace
London,
United Kingdom
|
+$83.7K |
| 2 |
AIM
Acrospire Investment Management
Chicago,
Illinois
|
+$77.2K |
| 3 |
VKH
Virtu KCG Holdings
New York
|
+$62.5K |
| 4 |
CG
Cutler Group
San Francisco,
California
|
+$54.7K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$42K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MCM
Marathon Capital Management
Hunt Valley,
Maryland
|
-$179K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$101K |
| 3 |
Morgan Stanley
New York
|
-$60.9K |
| 4 |
N
Natixis
Paris,
France
|
-$57K |
| 5 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$42.1K |
NYMX Hedge Fund Activity: Q4 2016 in Review
29 of the 4,008 institutional investors tracked by Wall St. Rank reported a position in Nymox Pharmaceutical Corp (NYMX) for Q4 2016, worth a combined $1.99M — down 20% from $2.48M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of NYMX and 5 opened new positions — a net loss of 1 holder — while 5 trimmed existing stakes and 5 added.
The largest buyer was Marshall Wace, opening a new position worth an estimated $83.7K. The largest seller was Marathon Capital Management, exiting entirely with an estimated $179K sold.
- 29 institutional investors held Nymox Pharmaceutical Corp (NYMX) as of Q4 2016, down from 30 in Q3 2016.
- Funds reported $1.99M of Nymox Pharmaceutical Corp stock for Q4 2016, down 20% quarter-over-quarter.
- 5 funds opened new Nymox Pharmaceutical Corp positions in Q4 2016 and 6 closed out, a net change of -1 holder.
- The largest Nymox Pharmaceutical Corp buyer in Q4 2016 was Marshall Wace, an estimated $83.7K added.
- The largest Nymox Pharmaceutical Corp seller in Q4 2016 was Marathon Capital Management, an estimated $179K sold.
Based on aggregated 13F filings for Q4 2016.